Next Century Growth Investors LLC Invests $1.89 Million in Guardant Health, Inc. $GH

Next Century Growth Investors LLC acquired a new position in shares of Guardant Health, Inc. (NASDAQ:GH) during the 4th quarter, Holdings Channel.com reports. The fund acquired 18,484 shares of the company’s stock, valued at approximately $1,888,000.

Several other institutional investors also recently modified their holdings of the company. First Turn Management LLC acquired a new stake in shares of Guardant Health during the 4th quarter worth approximately $27,750,000. Entropy Technologies LP lifted its position in shares of Guardant Health by 140.3% during the 4th quarter. Entropy Technologies LP now owns 17,093 shares of the company’s stock worth $1,746,000 after buying an additional 9,979 shares during the period. Arax Advisory Partners lifted its position in shares of Guardant Health by 61.5% during the 4th quarter. Arax Advisory Partners now owns 733 shares of the company’s stock worth $75,000 after buying an additional 279 shares during the period. Bullseye Asset Management LLC bought a new position in shares of Guardant Health during the 4th quarter worth approximately $102,000. Finally, Aigen Investment Management LP bought a new position in shares of Guardant Health during the 4th quarter worth approximately $215,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Analyst Upgrades and Downgrades

GH has been the subject of several analyst reports. BTIG Research set a $160.00 target price on Guardant Health and gave the stock a “buy” rating in a research report on Wednesday, May 27th. The Goldman Sachs Group initiated coverage on Guardant Health in a research report on Friday, June 5th. They set a “buy” rating and a $165.00 target price for the company. Stifel Nicolaus raised their target price on Guardant Health from $120.00 to $130.00 and gave the stock a “buy” rating in a research report on Friday, February 20th. Royal Bank Of Canada initiated coverage on Guardant Health in a research report on Thursday. They set an “outperform” rating and a $185.00 target price for the company. Finally, Raymond James Financial restated an “outperform” rating and set a $129.00 target price on shares of Guardant Health in a research report on Monday, February 23rd. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $141.95.

Insider Buying and Selling

In other news, Director Steve E. Krognes sold 9,294 shares of Guardant Health stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $132.51, for a total value of $1,231,547.94. Following the completion of the sale, the director directly owned 10,222 shares of the company’s stock, valued at approximately $1,354,517.22. This trade represents a 47.62% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Meghan V. Joyce sold 10,000 shares of Guardant Health stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $126.98, for a total value of $1,269,800.00. Following the completion of the sale, the director directly owned 11,183 shares of the company’s stock, valued at $1,420,017.34. This trade represents a 47.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 449,238 shares of company stock worth $51,164,492. 5.60% of the stock is currently owned by company insiders.

Guardant Health Price Performance

GH stock opened at $131.62 on Monday. The business has a fifty day moving average price of $103.51 and a 200 day moving average price of $102.08. Guardant Health, Inc. has a fifty-two week low of $40.35 and a fifty-two week high of $134.28. The stock has a market capitalization of $17.45 billion, a price-to-earnings ratio of -38.83 and a beta of 1.61.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.